26.9 C
Vientiane
Monday, July 7, 2025
spot_img
Home Blog Page 58

Jane Hunter’s Exclusive Wine Dinner at The Ritz-Carlton, Bali

The First Lady of New Zealand Wine elevates the sumptuous creations of The Beach Grill.

Download images: https://marrstar.box.com/s/6dhnite6qk6fm3vnvmm6kcsrkhtdolpz 

BALI, Indonesia , June 4, 2025 /PRNewswire/ — The Ritz-Carlton, Bali is proud to present an unforgettable evening of culinary excellence and world-class wine at Jane Hunter’s Wine Dinner, hosted at The Beach Grill on Thursday, 5 June 2025.

Guests are invited to indulge in an exclusive multi-course dinner paired with award-winning wines from Hunter’s Wines, one of New Zealand’s most celebrated wineries. Led by Jane Hunter, the iconic vintner often referred to as the “First Lady of New Zealand Wine,” the evening will offer guests a rare opportunity to experience the story, passion, and craftsmanship behind each glass.

“This is more than just a wine dinner,” says Go Kondo, General Manager of The Ritz-Carlton, Bali. “It’s an immersive experience that blends fine dining, legendary hospitality from our Ladies and Gentlemen, and one of the most respected names in New World wine.”

Each course of the evening’s menu will be thoughtfully curated by the resort’s culinary team to complement the unique notes and characteristics of Jane Hunter’s premium vintages, including the renowned Sauvignon Blanc, Rosé, and Pinot Noir selections.

With limited seating available, this exclusive event promises a sophisticated evening of gourmet cuisine, expertly paired wines, and personal insights from Simon Mitchell – Jane Hunter’s Wine Representative.

The event will start at 6 p.m. at The Beach Grill on 5 June 2025. The price is at IDR 1,600,000 nett per person including four-course set menu and Jane Hunter’s wine pairing.

For reservation please visit our website https://www.thebeachgrillbali.com/

About The Ritz-Carlton, Bali

Built on a sprawling 12.7 hectares white beach front and elevated cliff top  settings, The  Ritz-Carlton, Bali feature 313 oceanfront suites and villas, enjoying the unobstructed view of the Indian Ocean and the resort’s lush garden. Completing the experiences, a glass elevator connects the cliff and the beach-front, five restaurants and bars, The Ritz-Carlton Ballroom and meeting facilities, a wedding chapel, as well as The Ritz-Carlton Spa. Ladies and gentlemen at The Ritz-Carlton, Bali is proudly presents the timeless charms of Indo-Balinese hospitality.

About The Ritz-Carlton Hotel Company, LLC

Delivering the Gold Standard in service in coveted destinations around the world, The Ritz-Carlton Hotel Company, LLC currently operates more than 120 hotels in over 35 countries and territories. From iconic urban destinations to stretches of paradise in untouched corners of the earth, The Ritz-Carlton offers the opportunity for true discovery and transformative escapes that stay with guests long after they depart. Committed to thoughtful innovation, The Ritz-Carlton encompasses two groundbreaking brand extensions, Ritz-Carlton Reserve and The Ritz-Carlton Yacht Collection. Ritz-Carlton Reserve is a collection of rare estates set apart from the world, where personalized care and cultural immersion are paramount. The Ritz-Carlton Yacht Collection translates the brand’s legendary service and hospitality for sea, reimagining the ultra-luxury cruising category. For more information or reservations, visit the company website at www.ritzcarlton.com, for the latest company updates, visit news.marriott.com and to join the live conversation, use #RCMemories and follow along on Facebook, Twitter, and Instagram. The Ritz-Carlton Hotel Company, L.L.C. is a wholly-owned subsidiary of Marriott International, Inc. (NASDAQ:MAR). The Ritz-Carlton is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including complimentary nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. The Ritz-Carlton is committed to supporting the destinations where it operates through Community Footprints, the company’s social and environmental responsibility program.

WOGI Deepens Client and Merchant Ecosystem with UNIQGIFT Acquisition and New COO

By integrating UNIQGIFT and appointing Gregory Imbert as COO, WOGI enhances its operational strength to expand merchant partnerships and deepen client relationships.

SINGAPORE, June 4, 2025 /PRNewswire/ — WOGI, Asia’s trusted digital rewards and incentives solutions partner, today announced the acquisition of UNIQGIFT, Singapore’s leading provider of customised reward programs for customers, employees and partners. The deal, completed in late May, is part of WOGI’s strategy to scale strategic partnerships, extend client reach across Asia and grow its leadership capacity from its Singapore headquarters.

As part of the acquisition, UNIQGIFT CEO Gregory Imbert joins WOGI as Chief Operating Officer (COO) where he will lead the company’s partnerships and strategic alliances, oversee product development, and drive operational excellence across all markets. His appointment is a strategic move that reinforces WOGI’s commitment to strengthening enterprise support through direct, on-the-ground presence in key Asian markets—including Singapore, Malaysia, Hong Kong, Indonesia, Thailand, Vietnam, Japan, and Sri Lanka—while also accelerating its global reach and enhancing enterprise-grade service delivery.

“This strategic alignment reflects our commitment to intentional growth and client focus, enabling enterprises to manage personalised rewards and incentives at scale,” said Viktor Anastanov, CEO of WOGI. “It brings together two experienced players with deep knowledge of Asia’s cultural and operational complexity. Gregory brings a proven track record of client first execution and product innovation, further enhancing how we support clients across diverse markets.”

Reflecting on the integration and expanded reach, WOGI’s new COO, Gregory Imbert, noted: “Joining WOGI is an opportunity to extend what we built at UNIQGIFT into a broader platform which balances scale with a personal approach. Our clients gain access not only to a broader range of reward options across Asia, but also to WOGI’s powerful technology and enterprise-grade solutions that are designed to deliver seamless, scalable experiences.”

The integration unlocks new value for both UNIQGIFT clients and merchants partners. Clients previously limited to Singapore-only reward offerings now benefit from WOGI’s broader solution suite, regional service infrastructure, and merchant network spanning 47 markets. Merchant partners gain exposure to a wider client base, opening new opportunities to support campaigns and regional initiatives.

WOGI recently unveiled a new brand identity that reflects its mission to make rewards and incentives simple and meaningful across Asia and beyond. Since 2015, the company has served as a digital first platform built to address the complexities of Asia’s fragmented reward landscape. By unifying multiple currencies, thousands of brand partnerships, and robust compliance frameworks on a single platform, WOGI enables instant redemptions and seamless execution across the region.

Trusted by global organisations, WOGI powers millions of rewards and incentives that connect businesses with the people they serve across Asia and beyond. Its platform is built to serve the needs of diverse markets, combining local insight with global reach. It also offers enterprise level security and holds certification under ISO 9001:2015 and ISO/IEC 27001:2022. The company is backed by Blackhawk Network (BHN), a global leader in branded payments, which acquired a minority stake in 2022.

About WOGI

WOGI is an end-to-end digital rewards and incentives platform provider, designed to power rewards, performance, and loyalty across people and markets. WOGI enables organisations to deliver culturally relevant rewards and incentives that are simple to send and easy to manage. With local teams in eight Asian markets and coverage across 47 countries, WOGI brings together enterprises, brand partners, and payment networks to deliver impactful, culturally relevant rewards that reach people where it matters most.

Explore the platform at www.wogi.biz

About UNIQGIFT

Established in 2008, UNIQGIFT empowers organisations in Singapore to engage customers and employees in real time through innovative gifting, promotions, and loyalty solutions. UNIQGIFT is trusted by local government agencies, leading banks and insurance agencies. Its digital vouchers are accepted at top supermarkets, pharmacies, petrol stations, local cafes and more.

J.S. Held Announces the First Global Consulting Company Chief Intellectual Property Officer

JERICHO, N.Y., June 4, 2025 /PRNewswire/ — Global consulting firm J.S. Held proudly announces the appointment of intellectual property (IP) expert James E. Malackowski as the first Chief Intellectual Property Officer (CIPO) of a global consulting company. J.S. Held Chief Executive Officer Lee Spirer observes, “In today’s knowledge-based economy, the role of CIPO serves an important strategic and operational role both internally and in support of clients.” 

Protecting J.S. Held Intellectual Property and Other Intangible Assets

J.S. Held experts have developed methodologies, frameworks, proprietary tools, and research that support client work. The CIPO partners across the business to ensure that these intangible assets are identified, protected, and leveraged to benefit the business. “Having dedicated IP leadership will help the company move faster in developing and deploying new methodologies, while ensuring reasonable measures of protecting our innovations,” noted James E. Malackowski.

Managing J.S. Held Intellectual Property and Other Intangible Assets

J.S. Held maintains a robust portfolio of patents including a “System and Method for Financing an Insurance Transaction”, trademarks, data, trade secrets, and other proprietary technologies that support client work. “As CIPO, I intend to partner with company leadership and our professional experts across the globe to manage and monetize the many patent, trademark, data, and other proprietary assets that set J.S. Held apart among our competitors, benefitting clients and our investors,” added James E. Malackowski. 

Industry’s Most Comprehensive Global Intellectual Property Consulting Group

Ocean Tomo, a part of J.S. Held, is rooted in an expansive understanding of intellectual property (IP) value and risk, providing a foundation of Expertise for the Innovation Economy™.  Built upon more than three decades of experience assessing IP in the most rigorous of venues – state, federal, and international courts, Ocean Tomo clients benefit from continuous feedback between litigation economic damage outcomes, transaction pricing, capital market valuations, debt financing terms, equity assessments, and deep technical insight.  The team possesses the most comprehensive and market-tested understanding of IP value. Financial, market, and technical experts uniquely understand the contributory value of patented inventions, know-how, brands, and copyrights that permeate every business, viewing IP not simply as an isolated asset, but as an integral component of enterprise value.

Multidimensional Intellectual Property-Informed Experts Benefit J.S. Held Clients

Intellectual property expertise permeates the global organization. Beyond the expertise within J.S. Held’s dedicated IP practice Ocean Tomo, a part of J.S. Held, multidisciplinary experts across J.S. Held combine intellectual property expertise to core specializations, including:

  • Artificial Intelligence (AI)
  • Business Intelligence
  • Construction Advisory
  • Enterprise Risk Management
  • Fraud Investigations
  • Forensic Accounting
  • Insurance Claims Consulting
  • Restructuring, Turnaround, Receivership, and Bankruptcy

J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies

Building upon the important Intangible Asset Market Value Study created by Ocean Tomo and accessed on more than 150,000 occasions, J.S. Held releases the study of the MSCI World Mid-Cap companies. As shown in the graph, intangible assets now command 72% of the MSCI World Mid-Cap market value. As of 2025, the intangible asset market value of the MSCI Mid-Cap World Index companies exceeds $8.3 trillion USD. 

Tangible and Intangible Asset Value Understanding

The depth and breadth of J.S. Held’s work in the property and casualty insurance market and Ocean Tomo’s work across all forms of intellectual property and other intangible assets uniquely combine to create a strong foundation in risk assessment, data analysis, global awareness, regulatory compliance, technological adaptability, and risk mitigation. Collectively, these skills better equip J.S. Held experts to assess business risk across diverse geographies, geopolitical landscapes, regulatory frameworks, and technological advancements for the benefit of our clients.  

Learn more about the new J.S. Held Chief Intellectual Property Officer, James E. Malackowski.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC top 50 Property & Casualty Insurers), and 71% of the Fortune 100 Companies.

Verdantix, in their Green Quadrant: Enterprise Risk Management Consulting Services (2025) report, benchmarks 15 of the most prominent enterprise risk management (ERM) advisors, identifying global consulting firm J.S. Held among the leading companies based on capabilities and momentum

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Find your expert.®

Contact
Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies
J.S. Held Intangible Asset Market Value Study of MSCI World Mid-Cap Companies

 

Video – https://www.youtube.com/watch?v=_Y2LBmohvJU 

 

TerraPay Secures Class B License from Bank Negara Malaysia to Strengthen Cross-Border Payments in APAC

KUALA LUMPUR, Malaysia, June 4, 2025 /PRNewswire/ — TerraPay, a global leader in digital cross-border payments, today announced that it has been granted a Class B license by Bank Negara Malaysia (BNM). This development marks a pivotal step in TerraPay’s expansion across Southeast Asia, reinforcing its commitment to enabling secure, real-time, and compliant cross-border payment solutions in one of the region’s most dynamic financial hubs.

Malaysia stands as one of the largest cross-border remittance and trade corridors in the Asia-Pacific region. With the new license, TerraPay is now well-positioned to support the country’s growing demand for efficient and transparent cross-border financial services. The license enables TerraPay to directly partner with Malaysian banks, licensed payment institutions, and enterprises to facilitate seamless inbound and outbound remittances, B2B payments, and wallet payouts. It also empowers TerraPay to deepen its collaboration with local financial institutions and fintechs, offering them access to its robust, interoperable, and API-driven payment infrastructure. This will enable partners to scale their cross-border offerings with confidence, while ensuring compliance with Malaysia’s regulatory standards.

“This license reinforces TerraPay’s commitment to building a seamless and compliant payments ecosystem across APAC. Malaysia is a key market, and we are excited to deepen partnerships that drive financial inclusion and innovation,” said Ambar Sur, Founder & CEO of TerraPay.

Sukesh Malliah, Vice President (APAC) at TerraPay, said, “Securing the Class B license from Bank Negara Malaysia is a proud milestone in TerraPay’s APAC journey. Malaysia is a strategic market with immense potential for cross-border remittances and trade. This license empowers us to directly collaborate with local banks and financial institutions, delivering real-time, secure, and compliant payment solutions. We remain committed to driving financial inclusion and innovation across the region, while enabling our partners to scale confidently across borders.”

Aligned with Malaysia’s digital financial inclusion goals, TerraPay’s infrastructure is designed to be future-ready, supporting real-time transactions, enhancing customer experience, and promoting financial access for underserved communities. The company’s technology-first approach ensures that partners can integrate quickly and scale efficiently.

As a licensed entity under BNM, TerraPay reaffirms its dedication to upholding the highest standards of compliance, customer protection, and innovation. This milestone further strengthens TerraPay’s global regulatory footprint and underscores its mission to simplify global payments for everyone, everywhere.

About TerraPay

TerraPay simplifies global money movement, providing a single connection to one of the most expansive cross-border payment networks regulated in over 30 global markets. The platform enables payments to 150+ receiving countries, 210+ sending countries, over 3.7 billion mobile wallets, 7.5 billion bank accounts, and more than 12 billion cards. TerraPay is on a mission to create a borderless financial world, making money transfers instant, reliable, transparent, and fully compliant.

Founded in 2014, TerraPay has built the global digital wallet interoperable network, driving financial inclusion even in the most remote markets. TerraPay is headquartered in London, with offices in cities like Bangalore, Dubai, Bogota, Dar es Salaam, Kampala, and Singapore. Backed by leading investors including the IFC (World Bank), Prime Ventures, Partech Africa, and Visa, TerraPay continues its rapid global expansion.

 

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

News Summary

  • Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1
  • Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2
  • Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications.

BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ — 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency.

Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.
Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.

“Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape,” said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. “The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers.”

Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance.

Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing.

“Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed,” said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. “We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities.”

In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers.

The Xevo TQ Absolute XR Mass Spectrometer is available to order now.

Additional Resources

Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation.

ABOUT:

Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Contact:

Molly Gluck
Head of External Communications
Waters Corporation
molly_gluck@waters.com
Mobile: +1.617.833.8166

  1. Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed.
  2. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic]

 

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO), following IBI363’s other two oral presentations in colorectal cancer and melanoma. A manageable safety profile, encouraging efficacy, and trends in long-term survival benefits have been observed in both immunotherapy-resistant squamous non-small cell lung cancer (NSCLC) and wild-type lung adenocarcinoma. It is worth mentioning that Innovent’s pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference’s total oral presentations.

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year’s ASCO meeting, three oral presentations of IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—NSCLC, CRC, and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug’s novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the data cutoff date, April 7, 2025, a total of 136 patients with NSCLC had received IBI363 monotherapy (2 μg/kg QW~4mg/kg Q3W), including 67 with squamous cell carcinoma and 58 with EGFR wild-type adenocarcinoma.

IBI363 showed breakthrough therapeutic potential from tumor response to long-term survival benefit in immuno-resistant squamous NSCLC

  • All 67 squamous NSCLC patients were EGFR wild type. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportion of ≥2 lines of previous systemic therapy was 64.3% (18/28) vs 67.7% (21/31), the proportion of previous anti-PD-1/PD-L1 therapy was 100% (28/28) vs 96.8% (30/31) and the proportion of PD-L1 TPS<1% was 35.7% (10/28) vs 41.9% (13/31).
  • In the 1/1.5 mg/kg dose group, promising ORR/DCR/PFS/OS were observed. Median OS achieved 15.3 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 1/1.5 mg/kg dose group, the 3 mg/kg Q3W dose group observed more prominent confirmed ORR (36.7%), DCR (90.0%), PFS (median PFS 9.3 months) and OS trends (median OS not reached, 12-month OS rate 70.9%) (see the table below).

Squamous NSCLC

1/1.5 mg/kg

(n=28)

3 mg/kg

(n=31)

Confirmed ORR, % (95% CI)*

25.9 (11.1, 46.3)

36.7 (19.9, 56.1)

DCR, % (95% CI)*

66.7 (46.0, 83.5)

90.0 (73.5, 97.9)

Median PFS, month (95% CI)

5.5 (1.5, 8.3)

9.3 (6.2, 11.7)

Median PFS follow up time, month (95% CI)

16.5 (14.1, 19.5)

11.3 (10.1, 14.0)

Median OS, month (95% CI)

15.3 (7.6, NC)

NC (10.4, NC)

12-month OS rate, % (95% CI)

58.2 (37.3, 74.3)

70.9 (49.5, 84.5)

Median OS follow up time, month (95% CI)

17.3 (15.3, 20.2)

11.3 (10.3, 11.6)

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment.

  • Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg/kg group (N=13) were 46.2% and 92.3%, suggesting the potential advantage of IBI363 in the population with low expression of PD-L1.

IBI363 showed potential for long-term survival benefits in immuno-resistant wild-type lung adenocarcinoma, especially in patients with smoking history

  • Among the 58 patients with EGFR wild-type lung adenocarcinoma, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, 25 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportions of ≥2 lines of previous systemic therapy were 80.0% (24/30) vs 64.0% (16/25), the proportions of previous anti-PD-1/PD-L1 therapy were both 100%, the proportions of PD-L1 TPS<1% were 26.7% (8/30) vs 40.0% (10/25) and the proportions of smoking history were 56.7% (17/30) vs 60.0% (15/25).
  • In the 1/1.5 mg/kg dose group, median OS achieved 17.5 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 0.6/1/1.5 mg/kg dose group, the 3 mg/kg dose group observed higher confirmed ORR (24.0%), DCR (76.0%), PFS (median PFS 5.6 months) and OS trends (median OS not reached, 12-month OS rate 71.6%) (see the table below).

EGFR wild type adenocarcinoma

0.6/1/1.5 mg/kg

(n=30)

3 mg/kg

(n=25)

Confirmed ORR, % (95% CI)*

13.8 (3.9, 31.7)

24.0 (9.4, 45.1)

DCR, % (95% CI)*

62.1 (42.3, 79.3)

76.0 (54.9, 90.6)

Median PFS, month (95% CI)

2.7 (1.4, 5.1)

5.6 (3.1, 9.4)

Median PFS follow up time, month (95% CI)

21.9 (3.1, 21.9)

10.1 (6.1, 11.2)

Median OS, month (95% CI)

17.5 (5.6, NC)

NC (9.4, NC)

12-month OS rate, % (95% CI)

58.2 (38.3, 73.8)

71.6 (45.9, 86.6)

Median OS follow up time, month (95% CI)

17.7 (17.1, 20.9)

10.2 (9.1, 11.4)

* Note: one patient in 0.6/1/1.5mg/kg group finished treatment without at least one post-baseline tumor assessment.

  • Higher ORR and PFS were observed in lung adenocarcinoma patients with a history of smoking. Among them, the confirmed ORR in the 0.6/1/1.5 mg/kg group (N=17) was 23.5%, and the confirmed ORR in the 3 mg/kg group (N=15) was 33.3%. In all dose groups (N=32), the median PFS of smokers was longer than non-smokers: 5.3 (2.0, 7.0) vs 3.0 (1.6, 5.1) months. In terms of long-term survival benefits, after follow-ups of 12.0 and 13.7 months, the median OS for non-smokers was 13.6 months, whereas the median OS for smokers was not yet reached, with only 9 (28.1%) events occurring.

IBI363 had a manageable safety profile in advanced NSCLC

  • Among the 57 patients with NSCLC in the 3 mg/kg dose group, the most common treatment related adverse events (TRAEs) of grade 3 or above were arthralgia and rash. 7.0% of patients experienced TRAEs leading to discontinuation. The overall safety profile was manageable.

In view of the encouraging efficacy signals and manageable safety demonstrated by IBI363 monotherapy, Innovent plans to conduct a Phase 3 registration clinical study in locally advanced or metastatic squamous NSCLC that has failed platinum-based chemotherapy and anti-PD-1 /PD-L1 immunotherapy. As of now, IBI363 has received Breakthrough Therapy (BTD) certification from China CDE and Fast Track Designation (FTD) from the US FDA for squamous NSCLC.

Professor Jianya Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University, stated: “Lung cancer is the malignant tumor with the highest incidence and mortality rate both globally and in China[1], and it is a major issue endangering public health. Although immunotherapy has completely transformed the treatment landscape of NSCLC, for patients with wild-type NSCLC who have failed immunotherapy, the current standard treatment regimen docetaxel has limited efficacy, with an ORR of less than 20%, a PFS of less than 4 months, and an OS of less than 12 months [2-7]. In recent years, although the exploration of new treatment regimens such as immune combination therapy and antibody drug conjugates (ADCs) has brought new hope, many large-scale Phase 3 clinical studies on NSCLC patients who have failed platinum-based chemotherapy and immunotherapy have not achieved satisfactory results, and most of these studies have not met the primary endpoints[2-6]. Although the TROPION-Lung01 study achieved the primary endpoint of PFS in NSCLC, it did not reach the primary endpoint of OS. Especially in squamous NSCLC, no improvement was observed in PFS/OS/ORR in the experimental group. Therefore, there was a huge and urgent unmet medical need in NSCLC that has failed immunotherapy. As a PD-1/IL-2α-bias bispecific molecule, IBI363 not only shows clinical benefits in both ORR and PFS in immune-resistant NSCLC, but also enables us to see the potential of the tailing effect of immunotherapy to bring long-term survival benefits to patients compared with chemotherapy. We are also more looking forward to the survival data of the long-term follow up in the high dose IBI363 group.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “It is a great pleasure to orally present the latest progress of IBI363 in the field of lung cancer at the ASCO conference. IBI363 shows remarkable efficacy in immune-resistant wild-type nsclc and clinical data suggests better trends in ORR, DCR, PFS and OS at higher doses. We expect longer-term follow-up to bring more mature data and look forward to seeing its potential as an immunotherapy for the long-term survival benefits of patients. Meanwhile, regardless of the expression level of PD-L1, IBI363 has demonstrated a powerful anti-tumor effect in immune-resistant NSCLC (especially squamous NSCLC), suggesting that the effect of IBI363 does not depend on the expression of PD-L1. In the future, it may also bring breakthroughs in cold tumors with low or no expression of PD-L1. We will continue to advance the clinical exploration of IBI363 in NSCLC and other tumor types.”

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. 

In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1] Globocan 2022 (version 1.1) – 08.02.2024

[2] Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Aug 20 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733

[3] Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. Jul 10 2024;42(20):2393-2403. doi:10.1200/JCO.23.02166

[4] SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1. WCLC 2024.

[5] 65O – Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO IO 2023.

[6] Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer . 2024 Mar:189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16.

[7] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. Sep 9 2024:JCO2401544. doi:10.1200/JCO-24-01544

USI Partners with Customer on GPS Bike Computer Project, Delivering Durable Rugged Design

SHANGHAI, June 4, 2025 /PRNewswire/ — Universal Scientific Industrial (Shanghai) Co., Ltd., USI, a global leader in electronic design and manufacturing services, is collaborating with a customer to develop a GPS bike computer through its Joint Design Manufacturing (JDM) service. The project responds to increasing global demand for high-performance, durable cycling electronics in a rapidly expanding market.

According to a report by Global Industry Analysts, Inc., the global market for GPS bike computers was valued at $1.2 billion in 2024 and is expected to grow to $1.7 billion by 2030, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. This market is driven by rising interest in outdoor activities, fitness tracking, and smart mobility solutions. However, durability remains a top concern among end-users, particularly cyclists who operate in extreme environmental conditions and expect reliable performance from their gear.

With over two decades of experience in designing and manufacturing rugged, thinner, and lighter devices, USI is uniquely positioned to address these challenges. The company works closely with customers to understand their pain points and long-term product strategies. By analyzing the product roadmap and selecting key components, USI’s engineering team proposes a rugged design that emphasizes durability, reliability, and resistance to harsh conditions.

“Our JDM model allows customers to benefit from USI’s turnkey solutions—from concept design and system integration to volume production,” said Mark Zou, the Director of the Vertical Mobility Solutions Center, USI. For the GPS bike computer project, we delivered a robust design solution that meets both functional performance and ruggedness requirements, ensuring the device can withstand tough terrains, vibration, and weather elements.”

USI’s continued investment design expertise and customer-centric innovation supports the growing needs of the smart mobility market and reflects its commitment to quality, reliability, and partnership.

About USI (SSE: 601231)

USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. With Asteelflash and Hirschmann Car Communication, USI has 30 production and service locations across four continents of Asia, Europe, the Americas, and Africa, and offers customer diversified electronic products with D(MS)2 services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, and material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit www.usiglobal.com and engage with us on LinkedIn and YouTube.

Appian Connected Claims 2.0 Transforms Insurance Claims Management with AI

Appian is named a ‘Leader’ in Everest Group’s ‘AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix®’ for 2025

LONDON, June 4, 2025 /PRNewswire/ — Appian (NASDAQ: APPN) today announced the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow. Everest Group also named Appian a Leader in AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. Connected Claims 2.0 leverages Appian’s Case Management Studio, AI agents, and data fabric to offer streamlined, data-driven, and AI-powered automated processes.

Appian announces the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow.
Appian announces the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow.

Driven by rapid digital transformation, the global insurance claims services processing market is projected to reach $638.3 billion by 2032. Connected Claims 2.0 will support insurers through this growth with a unified claims workflow that accelerates processing, enhances fraud detection, combats inconsistent handling, data management issues and improves customer satisfaction. Connected Claims 2.0 offers a fully integrated, AI-powered platform with customisable workflows and a superior user experience, featuring a single pane of glass, AI-powered data insights, real-time data access, and automated regulatory compliance management.

Appian’s Connected Claims solution brings powerful AI-driven support to every adjuster, making it easier to manage the demands of a document-heavy claims environment. With capabilities like data classification, document summarisation, contextual chat, and next-best-action recommendations, AI accelerates work and improves decision-making. The next generation of the solution introduces the Appian AI Document Centre, enabling users to easily train models to extract data from unstructured documents. This means faster intake, more accurate data capture, and seamless handoff for tasks like fraud detection and automated triage. Over time, users can achieve high accuracy and boost straight-through processing (STP) rates—freeing human experts to focus only on the most complex cases. The result is faster, smarter claims handling with less manual work.

Trusted by companies like Aon, Canada Life, and Aviva, Appian has also been named a Leader in Everest Group’s AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. The assessment considered several factors, including each provider’s vision and strategy, technology capabilities, deployment flexibility, customer engagement models, support services, and overall value delivered. Appian’s recognition as a Leader highlights its strength in embedding AI directly into processes. This approach enables insurers to easily access powerful AI capabilities exactly when and where they’re needed—with just a few clicks.

“Appian’s Connected Claims solution, built on its low-code platform, combines AI-driven document processing, seamless third-party integrations, and configurable accelerators to deliver rapid time-to-value for P&C insurers,” said Aurindum Mukherjee, Practice Director at Everest Group. “Strong integration support across payment, risk, and fraud systems, coupled with proven success driving accelerated business value for insurers and high client satisfaction for implementation and support, underpins Appian’s position as a Leader in Everest Group’s AI-enabled Claims Management Systems PEAK Matrix® Assessment 2025.”

“We are launching Appian Connected Claims 2.0 to meet the urgent need for speed and early value realisation as the insurance industry tackles complexity, ” said Jake Sloan, Global Vice President of Insurance, Appian. “Our solution drives digital-first claims innovation, aligning with core admin cloud modernisation for early value realisation. It’s configurable, rapidly deployable, and leverages the latest powerful AI in Process to accelerate cycles, combat fraud, and personalise customer experiences. Connected Claims 2.0 empowers insurers to transform operations, balancing efficiency and accuracy with superior customer satisfaction, truly leading the evolution of claims management.”

Connected Claims 2.0 supports insurance companies, from claims adjusters, fraud detection teams, customer service representatives, regulatory compliance teams, to IT and operations teams.

About Appian

Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across various industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis.  All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions.
Everest Group’s PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com